Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer.
Yen-Cheng ChenHsiang-Lin TsaiChing-Chun LiChing-Wen HuangTsung-Kun ChangWei-Chih SuPo-Jung ChenTzu-Chieh YinChun-Ming HuangJaw-Yuan WangPublished in: PloS one (2021)
The long-term oncologic outcome of patients with LACC following concurrent chemoradiotherapy is acceptable, and the adverse effects seem to be tolerable. Pathologic N downstaging was an independent prognostic factor for patients' overall survival. However, a large prospective, randomized control study is required to confirm the current results.
Keyphrases
- locally advanced
- rectal cancer
- prognostic factors
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radiation therapy
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- double blind
- open label
- randomized controlled trial
- phase iii
- patient reported outcomes
- placebo controlled